Adalimumab for Crohn's disease in clinical practice at Mayo clinic: The first 118 patients
Inflammatory Bowel Disease, 04/05/2010
Loftus EV et al. – Adalimumab was both effective and well tolerated for the treatment of CD in this tertiary practice with a high prevalence of past infliximab exposure. This experience largely predates FDA approval of adalimumab for CD.